Today: 19 March 2026
FIGR stock leaps again before earnings as Figure Technology Solutions rallies off lows
26 February 2026
1 min read

FIGR stock leaps again before earnings as Figure Technology Solutions rallies off lows

New York, February 26, 2026, 09:09 EST — Premarket

  • FIGR looked ready to add another 1.5% before the bell, following up Wednesday’s 16.5% surge.
  • Figure Technology Solutions’ quarterly numbers drop after the bell, with investors on edge ahead of the release.
  • Traders have zeroed in on supply and demand since the recent blockchain-native share offering landed at $32.

Figure Technology Solutions shares looked set to open near $35.19 in early Thursday trading. On Wednesday, the stock jumped 16.5% to finish at $34.66, swinging between $30.13 and $35.28. Volume hit roughly 8.3 million shares. Barchart.com

Figure is on deck to deliver its fourth-quarter and full-year 2025 earnings after the bell, with a conference call to follow at 4:30 p.m. ET. In a release dated February 13, the company flagged preliminary Q4 consumer loan marketplace volume at $2.7 billion and estimated net revenue in a $158 million to $162 million range. GlobeNewswire

CEO Michael Tannenbaum pointed to “strong fourth quarter results” as evidence of Figure’s building momentum to wrap up the year, according to the release. GlobeNewswire

Why it matters now: FIGR shares have been quick to react since the September debut, and Thursday’s update marks one of the earliest major tests after the company put out those initial ranges. Investors want to see if management nails down 2026 guidance with more detail, plus offers deeper insight into how much revenue is coming from the loan marketplace versus tech fees.

Figure didn’t just stick to the sidelines in capital markets. On February 18, it upsized and priced a secondary public offering, unloading 4.375 million shares of Series A Blockchain Common Stock at $32 apiece. The company also committed to buying back 312,500 Class A shares from underwriters for roughly $10 million. GlobeNewswire

The deal was framed as an effort to shift tradeable equity securities onto blockchain rails. Still, it served as a reminder for equity investors: when the stock moves, new issuance can appear fast.

Thursday morning saw a cautious mood across the broader tape. U.S. stock futures barely budged, with Nvidia’s numbers and a packed earnings calendar giving investors plenty to consider. Reuters

Still, FIGR has moved to its own beat lately, lurching in both directions as retail traders and fast-money players respond to headlines, offerings, and the company’s fresh disclosures as a newly public firm.

The risk is plain enough. Should audited results come in under those early estimates—or if guidance falls short—the stock might give up its gains in a hurry. Fresh specifics on regulatory issues or demand for blockchain-native shares could also quickly shift sentiment.

The next major event for investors: the company’s earnings, coming out after Thursday’s close. Management is set to discuss the numbers on their 4:30 p.m. ET call. GlobeNewswire

Stock Market Today

  • General Motors Shares Slide Amid Valuation Debate with Mixed Analyst Views
    March 18, 2026, 10:22 PM EDT. General Motors (GM) shares declined 0.7% recently, down about 9% over the past month, closing at $73.53. Despite near-term weakness, GM has delivered strong longer-term returns, including a 49.18% one-year total shareholder return. The stock trades about 39% below intrinsic value and 29% under the average analyst target of $95.04, raising questions about buying opportunities versus priced-in growth. A notable user narrative values GM at $41.79, suggesting overvaluation amid uncertain operations and delayed electric vehicle (EV) return on investment. Yet, GM's price-to-earnings ratio (P/E) of 20.9 is below its fair estimate of 27.5 and peers' 59, hinting at a possible margin of safety. Key risks include potential upside from North American earnings and software subscription growth.
Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play
Previous Story

Hims & Hers stock steadies in premarket as Citi cuts target, SEC probe keeps GLP-1 risks in play

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone
Next Story

Celldex Therapeutics (CLDX) stock slips in premarket after 24% rally on Phase 3 barzolvolimab milestone

Go toTop